studies

1192A AASLD ABSTRACTS HEPATOLOGY, October, 2015
cant effect on RFS between groups B and C (HR=1.17, 95%
CI=0.63–2.18; P=0.620). Conclusion: High-potent antiviral
agents (ETV or TDF) reduce the risk of HCC recurrence compared
to low-potent antivirals as well as no antivirals, especially
in patients with high viral titer.
Disclosures:
Yoon Jun Kim - Grant/Research Support: Bristol-Myers Squibb, Roche, JW Creagene,
Bukwang Pharmaceuticals, Handok Pharmaceuticals, Hanmi Pharmaceuticals,
Yuhan Pharmaceuticals; Speaking and Teaching: Bayer HealthCare
Pharmaceuticals, Gilead Science, MSD Korea, Yuhan Pharmaceuticals, Samil
Pharmaceuticals, CJ Pharmaceuticals, Bukwang Pharmaceuticals, Handok Pharmaceuticals
The following authors have nothing to disclose: Hongkeun Ahn, Jeong-Hoon Lee,
YOUNG CHANG, Joon Yeul Nam, Hyeki Cho, Young Youn Cho, Minjong Lee,
Jeong-Ju Yoo, Yuri Cho, Donghyeon Lee, Eun Ju Cho, Su Jong Yu, Jung-Hwan
Yoon, June Sung Lee
2017
Long term follow up of chronic hepatitis B patients after
oral antiviral treatment discontinuation
Seong Hee Kang, Jong Eun Yeon, Young-Sun Lee, Tae Suk Kim,
Yang Jae Yoo, Ji Hoon Kim, Kwan Soo Byun; Gastroenterology &
Hepatology, Korea University Medical Center, Seoul, Korea (the
Republic of)
Introduction: In the current guidelines, 6-12 months of consolidation
after the HBeAg seroconversion is recommended for
HBeAg-positive patients. And the ideal treatment duration of
HBeAg negative chronic hepatitis B (CHB) is not well known.
We evaluated long term clinical courses in patient after antiviral
treatment cessation. Methods: A total of 118 HBeAg-positive
and 60 HBeAg-negative CHB patients who discontinued
lamivudine between 1997 and 2014 were retrospectively analyzed.
Results: In HBeAg-positive patients, the mean age of the
patients at treatment initiation was 32.5 years. The mean duration
of lamivudine treatment in was 32.3 months and the mean
follow-up period after discontinuation was 72.4 months. The
cumulative probability of a composite relapse (≥ 10 4 copies/
mL) at 1, 6, 12, 24, 48, 96, 180 months were 11.9%, 28.8%,
38.1%, 51.7%, 59.3%, 63.6%, 64.4% respectively. The mean
duration of lamivudine treatment were 31.9 months and 32.9
months in the relapse and non-relapse group (p=0.79). The
mean duration of consolidation period after HBeAg seroconversion
were 10.7 months and 11.4 months were not different
(p=0.792). Multivariate analysis revealed pretreatment age ≤
34 years [HR 0.324, 95% CI: 0.148-0.710 p=0.005] and
undetectable HBV DNA [HR 0.261, 95% CI: 0.107-0.638
p=0.003] within the three month after treatment discontinuation
were the predictive factors of non-relapse. In HBeAg-negative
patients, the mean age of the patients was 39.2 years.
The cumulative probability of a composite relapse at 1, 6, 12,
24, 48, 96, 180 months were 25.0%, 33.3%, 35.0%, 41.7%,
43.3%, 46.7%, 48.3% respectively. Mean time to relapse after
off-treatment was 13.6 months. The mean duration of lamivudine
treatment were 29.8 months and 33.5 months in the
relapse and non-relapse group (p=0.447). Conclusions: Even
with the long term consolidation after HBeAg seroconversion,
most HBeAg positive CHB patients showed relapse. And half
of patients with HBeAg-negative CHB had relapsed after treatment
cessation. Antiviral therapy should be maintained for long
term period or until HBsAg was lose.
Disclosures:
Kwan Soo Byun - Grant/Research Support: Gilead, BMS
The following authors have nothing to disclose: Seong Hee Kang, Jong Eun Yeon,
Young-Sun Lee, Tae Suk Kim, Yang Jae Yoo, Ji Hoon Kim
2018
The impact of timely initial injection of two different
doses of hepatitis B virus (HBV) vaccine plus hepatitis B
immunoglobulin (HBIG) on preventing perinatal transmission
of HBV infection
chong wang 1 , Chuan Wang 2 , Jie Li 3 , xing Wu 2 , Fei Kong 1 , Simin
Wen 2 , Jing Jiang 2 , Junqi Niu 1 ; 1 hepatology, The First Hospital of
Jilin University, Changchun, China; 2 The First Hospital of Jilin University,
Changchun, China; 3 Department of microbiology, Beijing
university, Beijing, China
Background & aims: Routine immunoprophylaxis reduces HBV
transmission. However, it does not have individual vaccine
dose to babies whose mothers with different hepatitis B virus e
antigen (HBeAg) status. this study was to investigate the effectiveness
of an immunoprophylaxis protocol with two different
vaccine doses according to mothers’HBeAg(+/-) status and
timely initial injection on blocking mother-to-infant transmission
of HBV, and to evaluate potential risk factors associated with
immunoprophylaxis failure and protective antibody titers. Methods:
A population-based prospective study was conducted from
July 2012 to April 2015. A total of 863 hepatitis B virus surface
antigen(HBsAg)-positive mothers and their 871 infants (8
pairs of twins) were included in the study. The initial injection
of HBV vaccine and HBIG(100IU) were carried out within 2
hours of birth. 20mg and 10mg HBV vaccine were given to
babies born to HBeAg+ and HBeAg- mothers respectively. We
analyze the association of multiple risk factors with immunoprophylaxis
failure and vaccine response. Results: At 7 months,
no immunoprophylaxis failure was observed in 565 babies
born to HBeAg- mothers.Among 306 infants born to HBeAg+
mothers, 16 (5.2%) babies were immunoprophylaxis failure
(HBsAg-positive) at 7 months, with high HBV DNA load ≥8
log10 IU/ml (Crude OR:3.69, 95%CI:1.03-13.24; Adjusted
OR:4.53, 95%CI a :1.19-17.34; P a =0.027) and Non timely
or inadequate initial injection (Crude OR:3.42, 95%CI:1.12-
10.49; Adjusted OR:5.23, 95%CI a :1.54-17.82; P a =0.008)
were strongly associated with immunoprophylaxis failure,
while other factors including delivery mode, feeding pattern,
infant gender and birth weight showed no significant association.
Of 855 babies for whom blocking was successful,
825(96.5%) had produced adequate titers of antibody to
HBsAg (anti-HBs) (≥ 100 mIU/mL). For full-term babies, birth
weight< 3000 g was correlated with low immune response
to vaccination (Crude OR:0.37, 95%CI:0.17-0.84; Adjusted
OR:0.37, 95%CI a :0.16-0.84; P a =0.018). Conclusions: Application
of timely initial injection of two different doses of HBV
vaccine plus HBIG to infants born to mothers with different
HBeAg status is effective for preventing perinatal transmission
of HBV, particularly for those whose mothers are HBeAg-negative.
The overwhelming majority of babies produced adequate
levels of protective anti-HBs titers (>100 mIU/mL) after immunoprophylaxis.
high HBV DNA load, and non-timely or inadequate
initial injection were associated with immunoprophylaxis
failure. Relative low birth weight of full-term babies might be
correlated with weak immune response to vaccination.
Disclosures:
The following authors have nothing to disclose: chong wang, Chuan Wang, Jie
Li, xing Wu, Fei Kong, Simin Wen, Jing Jiang, Junqi Niu